

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

September 27, 2004

Date of Report (date of Earliest Event Reported)

ISOLAGEN, INC.

(Exact Name of Registrant as Specified in its Charter)

DELAWARE

(State or Other Jurisdiction of Incorporation or Organization)

001-31564

(Commission File No.)

87-0458888

(I.R.S. Employer Identification No.)

2500 Wilcrest, 5th Floor, Houston, Texas 77042

(Address of principal executive offices and zip code)

(713) 780-4754

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
-
-
-

Item 1.01 Entry into a Material Definitive Agreement.

Effective September 27, 2004, Isolagen, Inc. ("Isolagen") and Mr. Dennis L. Bevan entered into an employment agreement (the "Agreement") pursuant to which Mr. Bevan agreed to serve as Isolagen's Vice President International Commercial Operations from September 27, 2004 until September 30, 2005. The Agreement provides for an annual salary of \$200,000, and, beginning in fiscal 2005, a merit-based bonus to be determined based upon mutually agreeable criteria. For fiscal 2004, Mr. Bevan shall receive a bonus of \$10,000. Under the Agreement, Mr. Bevan was issued a five-year option to purchase 150,000 shares of Isolagen common stock at an exercise price equal to the average market value of the common stock during the ten days preceding the issuance, which vests ratably on an annual basis over three years. The vesting provisions of the option would accelerate and Mr. Bevan would be entitled to a severance payment equal to his base salary for the greater of twelve months or the remainder of the term of the Agreement, if Mr. Bevan were terminated without "cause," or if Mr. Bevan were to terminate his employment with Isolagen for "good reason" (each of the terms as defined in the Agreement). During any period in which severance payments are being made, Mr. Bevan has agreed not to compete with Isolagen.

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(a) Not applicable.

(b) Not applicable.

(c) (1) Commencing September 27, 2004, Isolagen appointed Mr. Dennis L. Bevan to serve as Isolagen's Vice President International Commercial Operations.

(2) Mr. Bevan, age 59, has not served with Isolagen in any capacity prior to his appointment as Vice President International Commercial Operations. There are no familial relationships between Mr. Bevan and any director or executive officer of Isolagen. Since 1994, Mr. Bevan has been employed by Dermik Laboratories, Inc. in various capacities. Since September, 2001, Mr. Bevan served as Senior Director, U.S Sales. From January 2000 until September 2001, Mr. Bevan served as Senior Director, Strategic Communication, e-Business and Commercial Operations, Asia. From April 1998 until January 2000, Mr. Bevan served as Director, International Commercial Operations and General Manager of Shandong Dermik Pharmaceutical Company.

(3) See Item 1.01 for a discussion of the employment agreement between Isolagen and Mr. Bevan.

(d) Not applicable.

Item 9.01 Financial Statements and Exhibits

(a) Not applicable.

(b) Not applicable.

(c) Exhibits.

99.1 Press release dated September 30, 2004

[THE SIGNATURE PAGE FOLLOWS.]

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ISOLAGEN, INC.

Date: September 30, 2004

By: /s/ JEFFREY TOMZ

Chief Financial Officer

QuickLinks

[Item 1.01 Entry into a Material Definitive Agreement.](#)

[Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.](#)

[Item 9.01 Financial Statements and Exhibits](#)

[SIGNATURE](#)

Thursday, September 30, 2004, 1:00 PM Eastern Time
Press Release

SOURCE: Isolagen, Inc.

**DENNIS L. BEVAN APPOINTED AS ISOLAGEN'S
VICE PRESIDENT INTERNATIONAL COMMERCIAL OPERATIONS**

HOUSTON—(PRNewswire)—September 30, 2004—Isolagen, Inc. (AMEX: ILE) is pleased to announce that its Board of Directors appointed Dennis L. Bevan as Vice President of International Commercial Operations of Isolagen.

Mr. Bevan brings to Isolagen more than 30 years of progressive national and international experience in sales, marketing and general management in the pharmaceutical industry. He recently served as Senior Director of U.S. Sales for Dermik Laboratories, Inc. where he was involved in leading and directing the activities of a large sales organization in the United States. As Vice President of International Commercial Operations of Isolagen, Mr. Bevan will call on his prior experience as the Senior Director in Dermik's Asian operations where he successfully managed the establishment of an Asian joint venture pharmaceutical company taking it from start up to full and continuing operation with full P&L responsibility, and built a manufacturing plant. In addition Mr. Bevan established Dermik's Canadian business and served as General Manager in Canada.

Isolagen will utilize Mr. Bevan's experience of building strong relationships with government officials at federal, municipal, and provincial levels which are critical to operating in foreign markets. In addition, Mr. Bevan, who previously directed the successful launch of several major products in the European Union, and served as Managing Director of the Swiss subsidiary of a US pharmaceutical company, will be instrumental in the creation and implementation of its international marketing effort including pre-marketing and launch programs for the Isolagen Process.

"Dennis' experience in managing operations and commercializing new products in the U.S., European and Asian markets will be invaluable to Isolagen as we look to expand our commercial operations in foreign markets and launch the Isolagen Process in the United States," said Frank Delape, Chairman of Isolagen. "We look forward to the immediate contributions Dennis will make to our management team in this capacity."

About Isolagen, Inc.

Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The Company's product candidates are based on its proprietary Isolagen Process. Based on the accumulated experience of the Company through its retrospective study, clinical trials and treatment of patients in the United Kingdom, the Company believes that the Isolagen Process utilizes the patient's own cells to create safe and effective therapies to treat the underlying cause of the patient's condition. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and actual results may differ materially from the forward-looking statements. Isolagen, Inc. does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

Isolagen's corporate headquarters are located in Houston, TX. For further information, please see <http://www.isolagen.com>.

Contact:

Jeffrey W. Tomz, Chief Financial Officer and Secretary—(713) 780-4754
Kate McNeil, Investors Contact, Investor Relations Group—(212) 825-3210
John Nesbett, Investors Contact, Investor Relations Group—(212) 825-3210

QuickLinks

[Exhibit 99.1](#)